JAK/STAT Signaling

JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC50s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively.

JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics.

PROTAC EGFR degrader 8 (T-184) is a PROTAC EGFR degrader.

STAT6-IN-2 (Comp R-84) is an inhibitor of STAT6.

DZD1516 is a potent and selective HER2 inhibitor (IC50=0.56 nM) with good blood-brain permeability.

YS-363 is a potent, selective, and orally active EGFR inhibitor, with IC50s of 0.96 nM and 0.67 nM for wild-type and L858R mutant forms of EGFR, respectively.

Os30, a potent fourth-generation EGFR inhibitor, is a potent EGFRC797S-TK inhibitor with IC50 values of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively.

YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins).

MAPK-IN-2 (compound 3h) is a potent MAPK inhibitor with antineoplastic activity.

JAK3-IN-14 (compound 1) is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively.

STAT3-IN-20 (Compound 40) is a selective STAT3 inhibitor (IC50: 0.65 μM).

HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor.

IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma.

YS-67 is a potent inhibitor of EGFR with an IC 50 of 5.2 nM.

EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of L858R EGFR and AURKB with IC50s of 0.07 and 1.1, respectively.

Osimertinib-13C,d3 is the deuterium and 13C labeled Osimertinib.

T-1-PMPA is a potent EGFR inhibitor with apoptotic properties.

SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer.

STAT6-IN-4 (78) is a STAT6 inhibitor, with an IC50 of 0.34 μM.

STAT3-IN-25 (compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent.

iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110).

Pim-1 kinase inhibitor 8 (compound 12) is a potent inhibitor of Pim-1 kinase with an IC50 of 14.3 nM.

HNPMI is an inhibitor of EGFR and has cytotoxic effects on tumor cells.

MTX-531 is an oral drug that inhibits EGFR (with an IC50 of 14.7 nM) and PI3K (with IC50 values of 6.4, 233, 8.3, and 1.1 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ respectively), and it has anti-tumor effects.